NF-κBp65-specific siRNA inhibits expression of genes of COX-2, NOS-2 and MMP-9 in rat IL-1β-induced and TNF-α-induced chondrocytes

Osteoarthritis and Cartilage

Volumn 14, Issue 4, 2006, Pages 367-376

  Lianxu, C ^a   Hongti, J ^a   Changlong, Y ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Articular chondrocytes; COX 2; IL 1 ; MMP 9; NF Bp65; NOS 2; siRNA; TNF

Indexed keywords

CYCLOOXYGENASE 2; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; SMALL INTERFERING RNA; SYNAPTOTAGMIN; TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN 1;

ANIMAL CELL; ARTICLE; CARTILAGE CELL; CELL CULTURE; CONTROLLED STUDY; DENSITOMETRY; DRUG MECHANISM; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE SILENCING; MALE; NONHUMAN; NONVIRAL GENE THERAPY; OSTEOARTHRITIS; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING; ANIMAL; ARTICULAR CARTILAGE; BIOSYNTHESIS; DRUG ANTAGONISM; GENETICS; KNEE OSTEOARTHRITIS; METABOLISM; PATHOLOGY;

ANIMALS; CARTILAGE, ARTICULAR; CHONDROCYTES; CYCLOOXYGENASE 2; INTERLEUKIN-1; MATRIX METALLOPROTEINASE 9; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; OSTEOARTHRITIS, KNEE; RATS; RNA, SMALL INTERFERING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33747671487     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2005.10.009     Document Type: Article

References (78)

1. Hamerman D. The biology of osteoarthritis. N Engl J Med 320 (1989) 1322-1330
2. Shikhman A.R., Kuhn K., Alaaeddine N., and Lotz M. N-Acetylglucosamine prevents IL-1β-mediated activation of human chondrocytes. J Immunol 166 (2001) 5155-5160
3. Badger A.M., Cook M.N., Swift B.A., Newman-Tarr T.M., Gowen M., and Lark M. Inhibition of interleukin-1-induced proteoglycan degradation and nitric oxide production in bovine articular cartilage/chondrocyte cultures by the natural product, hymenialdisine. J Pharmacol Exp Ther 290 2 (1999) 587-593
4. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322 (1986) 547-549
5. Goldring M.B. The role of cytokine as inflammatory mediators in osteoarthritis: lessons from animal modes. Connect Tissue Res 40 (1999) 1-11
6. Dingle J.T., Saklatvala J., Hembry R., Tyler J., Fellb H.B., and Jubb R. A cartilage catabolic factor from synovium. Biochem J 184 (1979) 177-180
7. Saklatvala J., Pilsworth L.M., Sarsfield S.J., Gavrilovic J., and Heath J.K. Pig catabolin is a form of interleukin 1. Cartilage and bone resorb, fibroblasts make prostaglandin and collagenase, and thymocyte proliferation is augmented in response to one protein. Biochem J 224 (1984) 461-466
8. Clancy R.M., Amin A.R., and Abramson S.B. The role of nitric oxide in inflammation and immunity. Arthritis Rheum 41 (1998) 1141-1151
9. Goldring M.B., and Berenbaum F. Human chondrocyte culture models for studying cyclooxygenase expression and prostaglandin regulation of collagen gene expression. Osteoarthritis Cartilage 7 (1999) 386-388
10. Amin A.R., Attur M., Patel R.N., Thakker G.D., Marshall P.J., Rediske J., et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage, influence of nitric oxide. J Clin Invest 99 (1997) 1231-1237
11. Studer R., Jaffurs D., Stefanovic-Racic M., Robbins P.D., and Evans C.H. Nitric oxide in osteoarthritis. Osteoarthritis Cartilage 7 (1999) 377-379
12. Hashimoto S., Takahashi K., Amiel D., Coutts R.D., and Lotz M. Chondrocyte apoptosis and nitric oxide production during experimentally induced osteoarthritis. Arthritis Rheum 41 (1998) 1266-1274
13. Blanco F.J., Ochs R.L., Schwarz H., and Lotz M. Chondrocyte apoptosis induced by nitric oxide. Am J Pathol 146 (1995) 75-85
14. Cao M., Westerhausen-Larson A., Niyibixi C., Kavalkovich K., Georgescu H.I., Rizzo C.F., et al. Nitric oxide inhibits the synthesis of type-2 collagen without altering Col2a1 mRNA abundance: prolyl hydroxylase as a possible target. Biochem J 324 (1997) 305-310
15. Fernandes J.C., Martel-Pelletier J., and Pelletier J.P. The role of cytokines in osteoarthritis pathophysiology. Biorheology 39 (2002) 237-246
16. Nedelec E., Abid A., Cipolletta C., Presle N., Terlain B., Netter P., et al. Stimulation of cyclooxygenase-2-activity by nitric oxide-derived species in rat chondrocytes: lack of contribution to loss of cartilage anabolism. Biochem Pharmacol 61 (2001) 965-978
17. Dumond H., Presle N., Pottie P., Pacquelet S., Terlain B., Netter P., et al. Site specific change in gene expression and cartilage metabolism during early experimental osteoarthritis. Osteoarthritis Cartilage 12 (2004) 284-295
18. Hochberg M.C., Altman R.D., Brandt K.D., Clark B.M., Dieppe P.A., Griffin M.R., et al. Guidelines for the medical management of osteoarthritis. Part II Osteoarthritis of the knee. Arthritis Rheum 38 (1995) 1535-1540
19. Huskisson E.C., and Donnelly S. Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatology (Oxford) 38 (1999) 602-607
20. Ravaud P., Moulinier L., Giraudeau B., Ayral X., Guerin C., Noel E., et al. Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee: results of multicenter, randomized, controlled trial. Arthritis Rheum 42 (1999) 475-482
21. Baeuerle P.A., and Baltimore D. NF-kappa B: ten years after. Cell 87 (1996) 13-20
22. Barnes P.J., and Karin M. Nuclear factor κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336 (1997) 1066-1071
23. Conner E.M., and Grisham M.B. Inflammation, free radicals, and antioxidants. Nutrition 12 (1996) 274-277
24. Lin Y.L., Tsai S.H., Lin-Shiau S.Y., Ho C.T., and Lin J.K. Theaflavin-3,3′-digallate from black tea blocks the nitric oxide synthase by down-regulating the activation of NF-kB in macrophages. Eur J Pharmacol 367 (1999) 379-388
25. Tsai S.H., Lin-Shiau S.Y., and Lin J.K. Suppression of nitric oxide synthase and the downregulation of the activation of NF-κB in macrophages by resveratrol. Br J Pharmacol 126 (1999) 673-680
26. Hecker M., Preiss C., Klemm P., and Busse R. Inhibition by antioxidants of nitric oxide synthase expression in murine macrophages: role of nuclear factor-κB and interferon regulatory factor-1. Br J Pharmacol 118 (1996) 2178-2184
27. Xie Q.W., Kashiwabara Y., and Nathan C. Role of transcription factor NF-κB/Rel in induction of nitric oxide synthase. J Biol Chem 269 (1994) 4705-4708
28. Lopez-Collazo E., Hortelano S., Rojas A., and Bosca L. Triggering of peritoneal macrophages with IFN-alpha/beta attenuates the expression of inducible nitric oxide synthase through a decrease in NF-κB activation. J Immunol 60 (1998) 2889-2895
29. Vera M., Taylor B., Wang Q., Shapiro R.A., Billiarb T.R., and Geller D.A. Dexamethasone suppresses iNOS gene expression by upregulating I-κBa and inhibiting NF-κB. Am J Physiol 273 (1997) G1290-G1296
30. Newton R., Kuitert L.M., Bergmann M., Adcock I.M., and Barnes P.J. Evidence for involvement of NF-κB in the transcriptional control of COX-2 gene expression by IL-1β. Biochem Biophys Res Commun 237 (1997) 28-32
31. Ana M.B., Mara P., and Soraya L. Ethanol-induced iNOS and COX-2 expression in cultured astrocytes via NF-kB. Neuroreport 15 (2004) 681-683
32. Thanos D., and Maniatis T. NF-kappa B: a lesson in family values. Cell 80 (1995) 529-532
33. Baeuerle P.A., and Baltimore D. IkappaB: a specific inhibitor of the NF-kappa B transcription factor. Science 242 (1998) 540-546
34. De-Maetin R., Hoeth M., Hofer-Warbinek R., and Schmid J.A. The transcription factor NF-κB and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 20 (2000) E83-E88
35. Karin M., and Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 3 3 (2002) 221-227
36. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
37. Caplen N.J., Parrish S., Imani F., Fire A., and Morgan R.A. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci U S A 98 (2001) 9742-9747
38. Gouze J.N., Gouze E., Palmer G.D., Kaneto H., Ghivizzani S.C., Grodzinsky A.J., et al. Adenovirus-mediated gene transfer of glutamine: fructose-6-phosphate amidotransferase antagonizes the effects of interleukin-1 beta on rat chondrocytes. Osteoarthritis Cartilage 2 (2004) 217-224
39. Chow G., Nietfeld J.J., Knudson C.B., and Knudson W. Antisense inhibition of chondrocyte CD44 expression leading to cartilage chondrolysis. Arthritis Rheum 4 (1998) 1411-1419
40. Murakami T., Hirai H., Suzuki T., Fujisawa J., and Yoshida M. HTLV-1 Tax enhances NF-kappa B2 expression and binds to the products p52 and p100, but does not suppress the inhibitory function of p100. Virology 206 (1995) 1066-1074
41. Westacott C.I., and Sharif M. Cytokines in osteoarthritis: mediators or markers of joint destruction?. Semin Arthritis Rheum 25 (1996) 254-272
42. Goldring M.B. The role of the chondrocyte in osteoarthritis. Arthritis Rheum 43 (2000) 1916-1926
43. Evans C.H., and Robbins P.D. Potential treatment of osteoarthritis by gene therapy. Rheum Dis Clin North Am 25 (1999) 333-344
44. Attur E.G., Dave M.N., Leung M.Y., Cipolletta C., Meseck M., Woo S.L., et al. Functional genomic analysis of type II IL-1beta decoy receptor: potential for gene therapy in human arthritis and inflammation. J Immunol 168 (2002) 2001-2010
45. Baragi V.M. Technology evaluation: MFG-IRAP, University of Pittsburgh. Curr Opin Mol Ther 2 (2000) 216-220
46. Frisbie D.D., Ghivizzani S.C., Robbins P.D., Evans C.H., and McIlwraith C.W. Treatment of equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 9 (2002) 12-20
47. Chikanza I., and Femandes L. Novel strategies for the treatment of osteoarthritis. Expert Opin Invest Drugs 9 (2000) 1499-1510
48. Goldring M.B. Anticytokine therapy for osteoarthritis. Expert Opin Biol Ther 1 (2001) 817-829
49. Guincamp C., Pap T., Schedel J., Pap G., Moller-Ladner U., Gay R.E., et al. Gene therapy in osteoarthritis. Joint Bone Spine 67 (2000) 570-571
50. Janusz M.J., Hookfin E.B., Heitmeyer S.A., Woessner J.F., Freemont A.J., Hoyland J.A., et al. Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. Osteoarthritis Cartilage 9 (2001) 751-760
51. Frank D., William H., and Walker. Hormonal of the NF-κB signaling pathway. J Mol Endocrinol 157 (1999) 1-9
52. Tak P.P., and Firestein G.S. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107 1 (2001) 7-11
53. Autieri M.V., Yue T.L., Ferstein G.Z., and Ohlstein E. Antisense oligonucleotides to the p65 subunit of NF-κB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries. Biochem Biophys Res Commun 213 3 (1995) 827-836
54. Tomita T., Takeuchi E., Tomita N., Morishita R., Kaneko M., Yamamoto K., et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor κB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 42 (1999) 2532-2542
55. Olaf P., Juliane P., Christoph B., Claus V., and Robert B. Inhibition of NF-κB mediated inflammation by siRNA expressed by recombinant adeno-associated virus. J Virol Methods 120 (2004) 119-122
56. Roopashree S., Dwarakanath, Saurabh S., Marpadga A.R., Daniela C., John J.R., et al. Regulation of monocyte chemoattractant protein-1 by the oxidized lipid, 13-hydroperoxyoctadecadienoic acid, in vascular smooth muscle cells via nuclear factor-kappa B (NF-κB). J Mol Cell Cardiol 36 (2004) 585-595
57. Guo J. siRNA against NF-κBp65 subunit enhances sensitivity to chemotherapeutics. Immunotherapy Weekly 4 (2004) 37-42
58. Murano M., Maemura K., Hirata I., Toshina K., Nishikawa T., Hamamoto N., et al. Therapeutic effect of intracolonically administered nuclear factor κB (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis. Clin Exp Immunol 120 (2000) 51-58
59. Sharp P.A. RNA interference - 2001. Genes Dev 15 (2001) 485-490
60. Bernstein E., Caudy A.A., Hammond S.M., and Hannon G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409 (2001) 363-366
61. Grishok A., Pasquinelli A.E., Conte D., Li N., Parrish S., Ha I., et al. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell 106 (2001) 23-34
62. Hamilton A.J., and Baulcombe D.C. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 286 (1999) 950-952
63. Knight S.W., and Bass B.L. A role for the RNase III enzyme DCR-1 in RNA interference and germ line development in Caenorhabditis elegans. Science 293 (2001) 2269-2271
64. Zamore P.D., Tuschl T., Sharp P.A., and Bartel D.P. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101 (2000) 25-33
65. Hammond S.M., Caudy A.A., and Hannon G.J. Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet 2 (2001) 110-119
66. Stark G.R., Kerr M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Annu Rev Biochem 67 (1998) 227-264
67. Manche L., Green S.R., Schmedt C., and Mathews M.B. Interactions between double-stranded RNA regulators and the protein kinase DAI. Mol Cell Biol 12 (1992) 5238-5248
68. Hutvagner G., McLachlan J., Pasquinelli A.E., Balint E., Tuschl T., and Zamore P.D. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 293 (2001) 834-838
69. Jarvis R., and Ford L. The siRNA target site is an important parameter for inducing RNAi in human cells. Ambion Tech Notes (2001) 8
70. Elbashir S.M., Martinez J., Patkaniowska A., Lendeckel W., and Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 20 (2001) 6877-6888
71. Kuwabara P.E., and Coulson A. RNAi-prospects for a general technique for determining gene function. Parasitol Today 16 (2000) 347-349
72. INK4a-specific siRNA in vitro. Rheumatology 43 (2004) 555-568
73. Cao Z., Xiong J., Takeuchi M., Kurama T., and Goeddel D.V. TRAF6 is a signal transducer for interleukin-1. Nature 383 (1996) 443-446
74. MacMicking J., Xie Q.W., and Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 15 (1997) 323-350
75. Gao J., Morrison D.C., Parmely T.J., Russell S.W., and Murphy W.J. An interferon-γ-activated site (GAS) is necessary for full expression of the mouse iNOS gene in response to interferon-γ and lipopolysaccharide. J Biol Chem 272 (1997) 1226-1230
76. Kristof A.S., Marks-Konczalik J., and Moss J. Mitogen-activated protein kinases mediate activator protein-1-dependent human inducible nitric-oxide synthase promoter activation. J Biol Chem 276 (2001) 8445-8452
77. Djordje M., and Vladimir T. Inducible nitric oxide synthase activation by interleukin-17. Cytokine Growth Factor Rev 15 (2004) 21-32
78. Tak P.P., Gerlag D.M., Aupperle K.R., van-de-Geest D.A., Overbeek M., Bennett B.L., et al. Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis Rheum 44 (2001) 1897-1907